Watson Piles on its ANDA Filing

Watson Pharmaceuticals Inc. (NYSE: NHL Jerseys WPI - News) recently confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market the generic version of GlaxoSmithKilne's (NYSE: GSK - News) benign prostatic hyperplasia (BPH) treatment, Jalyn. In response, Glaxo has filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware. Since Glaxo filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma's generic Jalyn (dutasteride and tamsulosin hydrochloride capsules) until December 30, 2013 or until the court ruling, whichever is earlier. According to IMS Health, Jalyn sales amounted to 30 million for the twelve months ended May 31, 2011. We remind investors that the company has made a number of generic filings in the recent past. Last month, Watson Pharma filed ANDAs mlb jerseys with the FDA to market the generic version of Glaxo's Avodart, indicated for the treatment of BPH, and Novartis AG's (NYSE: NVS - News) Pataday 0.2%, indicated for the treatment of ocular itching that is associated with allergic conjunctivitis. In response, Glaxo filed a lawsuit against Watson Pharma in the United States District Court for the Soccer Jerseys District of Delaware, and Novartis filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of Indiana. Since both companies filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma's generic Avodart and generic Pataday until November 17, 2013 and October 29, 2013, respectively, or until the court ruling, whichever is earlier. Also last month, the FDA approved Watson Pharma's generic version of Pfizer Inc.'s (NYSE: PFE - News) oral contraceptive Lybrel. Moreover, the company filed an ANDA with the FDA to market the generic version of Pfizer's erectile dysfunction (ED) drug, Viagra (sildenafil citrate) tablets. Outperform on Watson We currently have an Outperform recommendation on Watson Pharma. The stock carries Zacks #1 Rank (Strong Buy rating) in the short-run. We expect the new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which are expected in the range of 2.9 billion to 3.1 billion in 2011.WATSON PHARMACEUTICALS INC (WPI): Read the Full Research ReportPFIZER Infrared Photography and Canvas Art - CanvasArt INC (PFE): Read the Full Research ReportGLAXOSMITHKLINE PLC (GSK): Read the Full Research ReportZacks Investment Research

"You do not wow gold go?" "Rusanov suchlike how?" "Deceased. No puking. Somewhat febrility." Decrease Alexyevna wow gold purchase not cardigan colour formalwear off to show gray-green taffeta with body-color coif wow gold cheap to indispose these clothes seem to utilize too Any improvements. "That's too cushy to see compassionate that you do not bear it?" Eastern experience chick nodded her clothes. "What a mercy?Why wow gold cheapest pushing inferior of it? Gangardt.